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Metachronic cancers in women with 
breast cancer and detected BRCA1 gene 
mutation
ABSTRACT
Introduction. Breast cancer is the most common malignancy in women, both worldwide and in Poland. Mutation 
in the BRCA1 gene is responsible for approximately 6% of all breast cancers in Poland diagnosed in patients 
under the age of 50 years. BRCA1-dependent cancers occur early and are frequently bilateral. The purpose of 
this thesis was to evaluate the frequency of metachronic cancers in a population of 42 patients with breast cancer 
with detected BRCA1 gene mutation.
Materials and methods. We analysed the health records of 196 patients with confirmed mutation in the 
BRCA1 gene, consulted between years 2005 and 2016 in the Genetics Outpatients Unit of the Maria Sklodows-
ka-Curie Memorial Cancer Centre and Institute of Oncology, Division in Cracow. Medical histories of 42 consecutive 
patients with breast cancer were selected for further analysis for metachronic cancers.
Results. During the observation period (median 10 years) 21 (50%) neoplasms metachronic to primary breast 
cancer were diagnosed. The most common was breast cancer of the contralateral breast, detected in 16 (38%) 
cases. Additionally, two synchronic breast cancers occurred, and in three other cases breast cancer was diag-
nosed as a metachronic neoplastic disease.
Conclusions. Taking into consideration the results of our study, we should improve awareness, in the medical 
community, of the scale of the problem of metachronic cancers in patients with diagnosed BRCA1 mutation. We 
should also consider intensifying the surveillance of female carriers of the BRCA1 gene mutation, who were treated 
for breast cancer in order to detect secondary neoplasms. Another important issue is to offer to each woman 
being a carrier of a BRCA1 gene mutation and previously treated for breast cancer a prophylactic mastectomy 
and a bilateral adnexectomy.
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Introduction
Breast cancer is the most common malignant 
neoplasm in women. The prevalence of breast cancer 
reaches 1.7 million and the death rate 0.5 million per 
year, worldwide [1]. Also in Poland breast cancer 
constitutes the most common cancer in women — the 
annual morbidity rate reaches more than 16 thousand, 
and the mortality rate is five thousand [2]. A continuous 
upward tendency of morbidity of breast cancer across 
all age groups is estimated for the years 2010–2025 [3]. 
The therapy has an interdisciplinary character, and 
according to the recommendations of the European 
Society of Breast Cancer Specialists (EUSOMA), 
should be conducted in a specialised oncological unites 
(so called breast units), dedicated to diagnosing and to 
treating only this disease entity [4]. The acknowledged 
factors increasing the risk of breast cancer are: older 
age, occurrence of breast cancer in the family, muta-
tions of the BRCA1 and/or BRCA2 gene, some benign 
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proliferative diseases of the breast, exposure to ionising 
radiation, prior prevalence of breast cancer, late age of 
first childbirth, early first period and late menopause, 
long-term hormone replacement therapy, and obesity 
in postmenopausal women [5]. BRCA1 is an extensive 
gene encoding a protein composed of 1836 amino ac-
ids. A potential spectrum of possible mutations is huge; 
however, de novo mutations rarely occur in this gene. 
This feature is probably responsible for the so-called 
‘founder effect’ [6]. The most common mutations de-
tected in the Polish population are 5382insC, C61G, 
and 4153delA [7–9], a fact which renders the genetic 
diagnostics of breast cancer patients and their relatives 
much easier. The real incidence of the BRCA1 gene 
mutation in the Polish population is difficult to evalu-
ate. Genetic background concerns probably 6% of 
breast cancer patients diagnosed under 50 years of age 
[10]. BRCA1 gene mutation-dependant breast cancers 
occur early (42–45 years old) and in 18–32% of patents 
are bilateral [10–13]. The presence of the BRCA1 gene 
mutation is related with a 50–80% risk of breast cancer 
development and with 40% [14, 15] risk of ovarian can-
cer occurrence, depending on the mutation type [15–17]. 
The aim of this thesis was to evaluate the incidence of 
the metachronic cancers in the population of breast cancer 
patients with a diagnosed mutation in the BRCA1 gene. 
Materials and methods 
We analysed the health records of 196 patients con-
sulted in the Genetics Outpatients Unit of the M. Cu-
rie-Sklodowska Memorial Cancer Centre and Institute 
in Cracow in the years 2005–2016, in order to identify 
breast cancer patients with detected BRCA1 gene muta-
tion. The medical records of 42 consecutive patients who 
had been diagnosed with a breast cancer were included 
in the further analysis. In all patients, BRCA1 gene 
mutations were detected after the diagnosis of a breast 
cancer, results were confirmed in two independent 
blood samples, and the presence of the mutation was 
appropriately documented by the treating physician in 
the health record of each patient. The health records 
of these patients were analysed for occurrence of me-
tachronic cancers, defined as a malignancy occurring 
over six months after the primary diagnosis of breast 
cancer [18]. Data concerning synchronic cancers and 
other neoplastic diseases that had occurred prior to 
the breast cancer diagnosis were additionally collected.
Results
In the analysed group of patients, the median of 
age at the breast cancer diagnosis was 45 years (range: 
26–79). The first symptoms of neoplastic disease were 
detected by breast self-exam in 22 patients, by physical 
exam by a physician in 12 patients, and by the control im-
aging exams (ultrasonography [US] or mammography) 
in eight patients. The performance status at the time of 
the diagnosis was defined as very good or good in all 
patients (according to the World Health Organisation 
PS 0 in 37 patients and PS 1 in another five). All patients 
underwent radical treatment. The median observation 
time was 10 years (range: 1–32). A metachronic cancer 
occurred in 21 (50%) patients: in 16 a cancer of the sec-
ond breast, two cases of the ovary cancer, one case of the 
sarcoma of the uterus, one case of the Kaposi sarcoma, 
and one case of the clear-cell renal cancer. Moreover, 
in two patients a bilateral synchronic breast cancer was 
diagnosed, and in two patients the breast cancer was 
a metachronic neoplasm (in both cases ovary cancer had 
been diagnosed 2 and 3 years prior to the diagnosis of 
the breast cancer). In one case, before the diagnosis of 
the breast cancer, a cervical cancer had been diagnosed 
(17 years earlier). In 26 (62%) breast cancer patients 
with a detected BRCA1 gene mutation a secondary, 
independent cancer occurred [median observation time 
was 10 years (range: 1–32)]; metachronic, synchronic or 
neoplastic disease reported in the health records before 
the diagnosis of the breast cancer. In the subgroup of 
21 patients in whom a neoplasm metachronic to primary 
breast cancer had been diagnosed, the median of time 
was 5.5 years (range: 1–17) from the date of the start 
of the therapy of the first breast cancer. During the 
observation time, in 17 patients a prophylactic hyster-
ectomy and bilateral adnexectomy were performed. No 
patient had a prophylactic mastectomy. The results are 
presented in Table 1. 
Discussion
In the general population, the risk of breast cancer 
occurrence is significantly higher in women who have 
already had breast cancer in the past. This risk equals 
10–15% for a 55-year-old woman with a history of breast 
cancer compared to a 2.5% risk for a healthy 55-year-old 
women over a 15-year observation time [19]. We esti-
mate that metachronic breast cancer may occur in 1% 
of the general population of patients previously treated 
for breast cancer, and the risk increases with time from 
the primary diagnosis [20, 21]. The risk of development 
of bilateral breast cancer in carriers of the BRCA1 gene 
mutation is significantly higher compared to the general 
population. In the analysed group a metachronic can-
cer was observed in 50% of patients and in 38% it was 
a cancer of the second breast. A relatively low incidence 
of ovarian cancer in the analysed population should be 
acknowledged — only two cases of metachronic cancer 
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Table 1. Independent malignant neoplasms in patients with 
breast cancer and BRCA1 mutation
Number of patients (n) 42
Median observation time (years) 10 (1–32)
Metachronic neoplasms (n/%) 21/50%
Median time to diagnosis of metachronic 
neoplasm (years)
5.5 (1–17)
Type of metachronic neoplasm (n):
— cancer of the second breast 
— ovary cancer
— sarcoma of the uterus
— Kaposi sarcoma
— renal carcinoma
16
2
1
1
1
Synchronic, bilateral breast cancers (n) 2
Malignant neoplasms diagnosed before the 
breast cancer; type of neoplasm (n):
— ovarian cancer
— cervical cancer
2
1
Independent malignant neoplasms inclusively (n/%) 26/62%
and two cases diagnosed prior the diagnosis of breast 
cancer (together 9.5%) compared to a 40% risk of ovar-
ian cancer defined in patients with detected BRCA1 gene 
mutation, as reported in the literature [14, 15]. This 
phenomenon may be partially explained by the fact 
that in 17 patients (40%) a prophylactic hysterectomy 
with bilateral adnexectomy was performed, as well as 
by a limited observation time. 
The therapy of breast cancer is becoming more and 
more effective. The five-year overall survival rate for 
Polish patients diagnosed in the years 1995–1999 equals 
73.8% [22], and in Europe 79% (ranging from 69% in 
the Czech Republic to 86% in Sweden) [23]. The prog-
nosis in the case of a bilateral breast cancer changes with 
the time from the primary diagnosis of the neoplasm 
with a longer time of overall survival in the process of 
time [24]. A paper by Gozdz et al. reported a 60.1% 
chance of five-year overall survival for patients with 
a metachronic cancer and 54% chance for those with 
a synchronic neoplastic disease [25].
Considering the prevalence of breast cancer and the 
significant population of patients who have undergone 
a radical therapy for breast cancer as well as relatively 
simple diagnostics for the presence of the BRCA1 gene 
mutation, we may expect that the number of patients 
post breast cancer therapy and with detected mutation 
will increase. The authors of this thesis, based on the pre-
sented result, postulate consideration of the following:
 — to improve in the medical community the awareness 
of the scale of metachronic neoplasms in patients 
with detected BRCA1 gene mutation;
 — to intensify the surveillance for secondary neoplasms 
in BRCA1 gene mutation female carriers who were 
previously treated for breast cancer;
 — to offer to each person previously treated for breast 
cancer, who is a carrier of the BRCA1 gene mutation, 
mastectomy and bilateral adnexectomy. 
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